Publications by authors named "Bijoyesh Mookerjee"

Claim this Profile
C
Canakinumab in combination with docetaxel compared with docetaxel alone for the treatment of advanced non-small cell lung cancer following platinum-based doublet chemotherapy and immunotherapy (CANOPY-2): A multicenter, randomized, double-blind, phase 3 trial.
Luis Paz-Ares, Yasushi Goto, Darren Wan-Teck Lim, Balazs Halmos, Byoung Chul Cho, Bijoyesh Mookerjee

Lung Cancer· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib monotherapy: Analysis from phase 2 and 3 clinical trials.
Axel Hauschild, Paolo A Ascierto, Dirk Schadendorf, Jean Jacques Grob, Antoni Ribas, Bijoyesh Mookerjee

Eur J Cancer· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Publisher Correction: Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma.
Antoni Ribas, Donald Lawrence, Victoria Atkinson, Sachin Agarwal, Wilson H Miller, Bijoyesh Mookerjee

Nat Med· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma.
Paolo Antonio Ascierto, Pier Francesco Ferrucci, Rosalie Fisher, Michele Del Vecchio, Victoria Atkinson, Bijoyesh Mookerjee

Nat Med· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma.
Antoni Ribas, Donald Lawrence, Victoria Atkinson, Sachin Agarwal, Wilson H Miller, Bijoyesh Mookerjee

Nat Med· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient-reported outcomes in patients with resected, high-risk melanoma with BRAF or BRAF mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trial.
Dirk Schadendorf, Axel Hauschild, Mario Santinami, Victoria Atkinson, Mario Mandalà, Bijoyesh Mookerjee

Lancet Oncol· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Five-year outcomes from a phase 3 METRIC study in patients with BRAF V600 E/K-mutant advanced or metastatic melanoma.
Caroline Robert, Keith Flaherty, Paul Nathan, Peter Hersey, Claus Garbe, Bijoyesh Mookerjee

Eur J Cancer· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of the effect of dabrafenib and metabolites on QTc interval in patients with BRAF V600-mutant tumours.
Noelia Nebot, Hendrik-Tobias Arkenau, Jeffrey R Infante, Jason C Chandler, Andrew Weickhardt, Bijoyesh Mookerjee

Br J Clin Pharmacol· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combined BRAF, EGFR, and MEK Inhibition in Patients with -Mutant Colorectal Cancer.
Ryan B Corcoran, Thierry André, Chloe E Atreya, Jan H M Schellens, Takayuki Yoshino, Bijoyesh Mookerjee

Cancer Discov· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Term Outcomes in Patients With BRAF V600-Mutant Metastatic Melanoma Who Received Dabrafenib Combined With Trametinib.
Georgina V Long, Zeynep Eroglu, Jeffrey Infante, Sapna Patel, Adil Daud, Bijoyesh Mookerjee

J Clin Oncol· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer.
Vivek Subbiah, Robert J Kreitman, Zev A Wainberg, Jae Yong Cho, Jan H M Schellens, Bijoyesh Mookerjee

J Clin Oncol· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma.
Georgina V Long, Axel Hauschild, Mario Santinami, Victoria Atkinson, Mario Mandalà, Bijoyesh Mookerjee

N Engl J Med· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dabrafenib plus trametinib in patients with previously untreated BRAF-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial.
David Planchard, Egbert F Smit, Harry J M Groen, Julien Mazieres, Benjamin Besse, Bijoyesh Mookerjee

Lancet Oncol· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials.
Dirk Schadendorf, Georgina V Long, Daniil Stroiakovski, Boguslawa Karaszewska, Axel Hauschild, Bijoyesh Mookerjee

Eur J Cancer· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dabrafenib plus trametinib in patients with BRAF-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial.
Michael A Davies, Philippe Saiag, Caroline Robert, Jean-Jacques Grob, Keith T Flaherty, Bijoyesh Mookerjee

Lancet Oncol· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase 1/1b Study Evaluating Trametinib Plus Docetaxel or Pemetrexed in Patients With Advanced Non-Small Cell Lung Cancer.
David R Gandara, Natasha Leighl, Jean-Pierre Delord, Fabrice Barlesi, Jaafar Bennouna, Bijoyesh Mookerjee

J Thorac Oncol· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial.
David Planchard, Benjamin Besse, Harry J M Groen, Pierre-Jean Souquet, Elisabeth Quoix, Bijoyesh Mookerjee

Lancet Oncol· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dabrafenib in patients with BRAF(V600E)-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial.
David Planchard, Tae Min Kim, Julien Mazieres, Elisabeth Quoix, Gregory Riely, Bijoyesh Mookerjee

Lancet Oncol· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pyrexia in dabrafenib-treated melanoma patients is not associated with common genetic variation or HLA polymorphisms.
Diptee Kulkarni, Kijoung Song, Linda Briley, Karen King, Christine Dabrowski, Bijoyesh Mookerjee

Pharmacogenomics· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.
Jean Jacques Grob, Mayur M Amonkar, Boguslawa Karaszewska, Jacob Schachter, Reinhard Dummer, Bijoyesh Mookerjee

Lancet Oncol· October 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial.
Georgina V Long, Daniil Stroyakovskiy, Helen Gogas, Evgeny Levchenko, Filippo de Braud, Bijoyesh Mookerjee

Lancet· August 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea.
Srdan Verstovsek, Francesco Passamonti, Alessandro Rambaldi, Giovanni Barosi, Peter J Rosen, Bijoyesh Mookerjee

Cancer· February 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cediranib in combination with fulvestrant in hormone-sensitive metastatic breast cancer: a randomized Phase II study.
David M Hyams, Arlene Chan, Celia de Oliveira, Raymond Snyder, Jeferson Vinholes, Bijoyesh Mookerjee

Invest New Drugs· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III).
Hans-Joachim Schmoll, David Cunningham, Alberto Sobrero, Christos S Karapetis, Philippe Rougier, Bijoyesh Mookerjee

J Clin Oncol· October 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cediranib monotherapy in patients with advanced renal cell carcinoma: results of a randomised phase II study.
Peter Mulders, Robert Hawkins, Paul Nathan, Igle de Jong, Susanne Osanto, Bijoyesh Mookerjee

Eur J Cancer· March 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis